文献速递糖尿病

钠-葡萄糖转运体2抑制剂对1型糖尿病心血管结局的影响:随机对照试验的系统综述与Meta分析

Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该系统综述与Meta分析纳入16篇随机对照试验,评估SGLT2i对1型糖尿病患者心血管结局的影响。结果显示,与安慰剂相比,SGLT2i显著降低糖化血红蛋白(MD -0.40%)和体重(MD -3.31 kg),未显著增加低血糖和严重低血糖风险,但显著增加糖尿病酮症酸中毒风险(RR 4.45)。

要点

  • SGLT2i显著降低1型糖尿病患者糖化血红蛋白(MD -0.40%)和体重(MD -3.31 kg)。
  • SGLT2i未显著增加低血糖和严重低血糖风险。
  • SGLT2i显著增加糖尿病酮症酸中毒风险(RR 4.45)。

核心结论

  • SGLT2i不仅显著改善1型糖尿病患者的糖化血红蛋白和体重,还显著增加糖尿病酮症酸中毒风险。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Scopus、Cochrane Library、Web of Science和Embase截至2024年6月30日的随机对照试验,共纳入16篇文章。

主要发现

  • 与安慰剂相比,SGLT2i显著降低使用胰岛素的1型糖尿病患者的糖化血红蛋白水平(MD -0.40%,95% CI -0.44至-0.36;P < .00001,I² = 37%)。
  • 与安慰剂相比,SGLT2i显著降低使用胰岛素的1型糖尿病患者的体重(MD -3.31 kg,95% CI -3.67至-2.96;P < .00001,I² = 70%)。
  • SGLT2i未显著增加低血糖和严重低血糖风险。
  • SGLT2i显著增加糖尿病酮症酸中毒风险(RR 4.45,95% CI 2.81-7.05,P < .00001,I² = 0%)。

关键数值与推荐

  • 糖化血红蛋白降低:MD -0.40%(95% CI -0.44至-0.36;P < .00001,I² = 37%)。
  • 体重降低:MD -3.31 kg(95% CI -3.67至-2.96;P < .00001,I² = 70%)。
  • 糖尿病酮症酸中毒风险:RR 4.45(95% CI 2.81-7.05,P < .00001,I² = 0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease is a major cause of increasing morbidity and mortality in type 1 diabetes mellitus (T1DM). Although insulin therapy is the cornerstone of T1DM, its difficult use and narrow therapeutic index make it difficult for patients to reach glycated hemoglobin targets, increasing the risk of cardiovascular events. Therefore, the combination of sodium-glucose transporter 2 inhibitors (SGLT2i) can likely improve or provide more cardiovascular benefits to patients with T1DM. METHODS: This study conducted a systematic review and meta-analysis of randomized controlled trials published in PubMed, Scopus, Cochrane Library, Web of Science, and Embase up to June 30, 2024. The data from eligible trials were summarized as mean difference (MD) and SD for continuous methods and 95% CI and risk ratio (RR) for dichotomous approaches. RESULTS: There were 16 articles that met the inclusion criteria. Compared with placebo, SGLT2i significantly reduced glycated hemoglobin levels (MD: -0.40%, 95% CI, -0.44 to -0.36; P < .00001, I2 = 37%), and body weight (MD: -3.31 kg, 95% CI, -3.67 to -2.96; P < .00001, I2 = 70%) in insulin-using patients with T1DM, and did not significantly increase the risk of hypoglycemia and severe hypoglycemia. It should be noted that SGLT2i significantly increased the risk of diabetic ketoacidosis acidosis (RR: 4.45, 95% CI, 2.81-7.05, P < .00001, I2 = 0%). CONCLUSION: SGLT2i not only significantly improved glycated hemoglobin and body weight in patients with T1DM but also significantly increased the risk of diabetic ketoacidosis acidosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang S, Zhang Y, Balati A, et al. Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2025. PMID: 39812177. doi:10.1210/clinem/dgaf016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。